Science Corporation Implants Vision Chip in Stargardt Patient
Science Corporation has implanted its PRIMA vision-restoring microchip into its first patient with Stargardt disease, an inherited condition that causes gradual central vision loss, according to TechCrunch. Max Hodak, CEO and co-founder of Science Corporation and former president of Neuralink, announced the milestone during an appearance at TechCrunch Disrupt.
The procedure involves placing a two-millimeter by two-millimeter chip into the back of the patient’s eye where photoreceptors have degenerated, serving as an artificial replacement. Patients then wear camera-equipped glasses that transmit visual data to the implant, converting visual input into electrical signals that travel down the optic nerve to the brain. The first Stargardt patient received the implant in May during a trial at the Sydney Eye Hospital in Australia, successfully reading letters and words during rehabilitation sessions.
While PRIMA is already commercially available in Europe for patients experiencing geographic atrophy from age-related macular degeneration, the company is testing its broader application for incurable conditions like Stargardt disease. The current device provides a high-contrast, black-and-white patch of central vision. Science Corporation is developing a next-generation implant expected to enter human trials within the next year, aiming to expand the field of view and achieve native visual acuity over the next five years.
Hodak positioned the retinal prosthesis as part of the company’s wider work in brain-computer interfaces and neural engineering. Founded in 2021, Science Corporation is pursuing medical technology applications that treat neurological conditions and extend human health span through hardware and neural interface infrastructure.
Based on reporting by techcrunch.com.
